CCN(C(C)C)C(C)C.[O:10]=[C:11]1[CH:16]=[CH:15][CH:14]=[CH:13][N:12]1[C:17]1[CH:25]=[CH:24][C:20]([C:21]([OH:23])=O)=[CH:19][CH:18]=1.C1C=CC2N(O)N=NC=2C=1.CCN=C=NCCCN(C)C.Cl.[NH2:48][CH2:49][C:50]([N:52]1[CH2:57][CH2:56][N:55]([C:58](=[O:69])[C:59]2[CH:64]=[CH:63][CH:62]=[CH:61][C:60]=2[C:65]([F:68])([F:67])[F:66])[CH2:54][CH2:53]1)=[O:51]>CN(C=O)C.O>[O:10]=[C:11]1[CH:16]=[CH:15][CH:14]=[CH:13][N:12]1[C:17]1[CH:18]=[CH:19][C:20]([C:21]([NH:48][CH2:49][C:50](=[O:51])[N:52]2[CH2:53][CH2:54][N:55]([C:58](=[O:69])[C:59]3[CH:64]=[CH:63][CH:62]=[CH:61][C:60]=3[C:65]([F:66])([F:68])[F:67])[CH2:56][CH2:57]2)=[O:23])=[CH:24][CH:25]=1DIPEA (213 mg, 0.27 mL, 1.65 mmol) was added to a stirred solution of 4-(2-oxo-2H-pyridin-1-yl)-benzoic acid (120 mg, 0.55 mmol) in DMF (2 mL). HOBT (74.5 mg, 0.55 mmol) and EDCI (126.5 mg, 0.66 mmol) were then added at room temperature. After 2 minutes, 2-amino-1-[4-(2-trifluoromethyl-benzoyl)-piperazin-1-yl]-ethanone hydrochloride salt (196 mg, 0.55 mmol) was added and the resulting mixture was stirred at room temperature overnight. Cold water was then added and filtered the solid precipitated out to afford 42 mg (14.7% yield) of 4-(2-Oxo-2H-pyridin-1-yl)-N-{2-oxo-2-[4-(2-trifluoromethyl-benzoyl)-piperazin-1-yl]-ethyl}-benzamide. LCMS Purity: 94.83%. 1H NMR (DMSO-d6): δ 8.0 (m, 2H), 7.9 (m, 2H), 7.7 (m, 2H), 7.5 (m, 4H), 6.5 (m, 1H), 6.4 (t, 1H), 4.2 (m, 2H), δ 3.9-3.6 (m, 4H), 3.5-3.4 (m, 2H), 3.2-3 (s, 2H).